The departure of Bayer Chairman Werner Wenning will turn up the heat on CEO Werner Baumann to resolve the healthcare to agriculture group’s legal problems, two of the firm’s biggest German shareholders said on Wednesday.
Bayer’s shares have plunged about a quarter in value since August 2018, when the company lost a U.S. lawsuit claiming that weedkiller Roundup – acquired via its $63 billion takeover of Monsanto earlier in the year – causes cancer.
Wenning, who strongly supported Baumann’s pursuit of Monsanto, said earlier on Wednesday he would step down at the company’s annual shareholder meeting in April.
He will be replaced by Norbert Winkeljohann, the former head of Europe at audit and consulting firm PricewaterhouseCoopers, who joined Bayer’s non-executive supervisory board in 2018 and did not play a role in the Monsanto deal.
“What speaks in favor of Winkeljohann is the fact that he can look at the Monsanto issue with fresh eyes,” said Ingo Speich, a fund manager at Deka Investment.
“That can be a challenge for Baumann, particularly in the difficult phase that the company is in,” he said, adding he did not think Baumann was in immediate danger of losing his job.
Janne Werning, in charge of environmental, social and governance issues at Union Investment, said Wenning’s departure came at the right time.
“Mr Wenning was closely associated with the current difficult situation. It’s now essential that Bayer’s further strategic positioning is subject to independent oversight,” he told Reuters in a written comment.
Both Speich and Werning were disappointed, however, that Winkeljohann has no expertise in running international healthcare or agriculture businesses.
That drawback is compounded by the fact another board nominee, the former finance chief of travel group TUI, Horst Baier, also brings no specific industry experience, said Union’s Werning.
Deka and Union are among Bayer’s top 20 investors, according to Refinitiv data. They declined to give the size of their holdings.
With the number of Roundup lawsuits rising, Bayer’s top management faced an unprecedented show of shareholder disapproval at last April’s annual general meeting.
The company is now in talks to settle the claims, with some analysts saying that could cost it up to $12 billion.
“As Mr Baumann has lost one of his most important supporters, his future in Bayer might be … uncertain and linked to the share price development of Bayer after the settlement announcement,” said Baader Helvea analyst Markus Mayer in a research note.
By Ludwig Burger
Source: Reuters
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”
